First-in-human dose-escalation study of the phosphatidylinositol 3-kinase α-selective inhibitor HS-10352 in advanced breast cancer

Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: a8d24732b99380b3d065dc6bbb1822fc9300a4f5
First added on: Feb 14, 2025